Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to conduct a clinical trial of two formulations of budesonide (nebulized/swallowed versus viscous/swallowed) in patients with EoE to determine if medication contact time and distribution in the esophagus relates to treatment response. The investigators will also determine if there is systemic absorption of these topical steroids. The investigators hypothesize that tissue and symptom response will correlate with esophageal medication contact time and distribution, and that significant systemic absorption will not be seen.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of North Carolina, Chapel Hill
• Collaborator: AstraZeneca
• Treatments: Budesonide

Criteria

Inclusion Criteria:

• New diagnosis of eosinophilic esophagitis (per 2007 consensus guidelines)

Exclusion Criteria:

• Age < 18

• Inability to read or understand English

• Pregnant or nursing women

• Previous allergic reactions to steroid medications

• Current use of systemic steroids